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RISK ENVIRONMENTS AND THE ETHICS OF REDUCING DRUG-RELATED HARMS 
C.R. McGowan, A.M. Viens, Magdalena Harris, Tim Rhodes 
People who use drugs (PWUD) are at risk of developing serious health problems, including injecting-
related injuries or infections. Traditionally, the locus of responsibility for mitigating the risk of injury 
and infection has been the individual—with public health interventions focusing on individual-level 
behavior change. However, the environment in which people use drugs may also confer risks that 
are often synergistic and, though their effects are manifest in the individual, exist beyond the 
individual’s locus of control. This “risk environment” can be defined as “the space—whether social 
or physical—in which a variety of factors interact to increase the chances of drug-related harm” 
(Rhodes 2002, 88). In the context of injection drug use, the risk environment confers both social risks 
(including discrimination and other factors that create social disadvantage) and physical risks 
(including violence, as well as harms resulting from impurities or adulterants in the drug supply). 
These features of the risk environment are ethically significant considerations that must be taken 
into account when assessing the appropriateness of particular therapeutic and research 
interventions for PWUD. 
The purpose of supervised injectable opioid assisted treatment (siOAT) is to mitigate the harms of 
injection drug use among treatment-refractory heroin users by providing a regular, controlled dose 
of diamorphine (or, as was the case with the SALOME trial, hydromorphone) in a supervised setting. 
Evidence establishes that siOAT can be acutely lifesaving (e.g., preventing overdose from fentanyl-
laced heroin acquired on the street) and/or chronically life-extending (e.g., providing substitution 
treatment for people who do not respond to conventional treatment). (Strang et al. 2015) Though 
the safety and efficacy of siOAT have been well established, concerns about the ethical permissibility 
of siOAT persist. Often these concerns focus on questions about the extent to which chronic 
treatment-resistant heroin users are able to provide informed consent. This concern has been raised 
by Charland (2002), Cohen (2002), Henden (2013), and others. 
Like Steel and colleagues, we argue that it is incorrect to assume that PWUD lack the decisional 
capacity to provide informed consent; however, we disagree with the authors’ approach to 
voluntariness, and with their use of an unnecessary distinction between the provision of siOAT as 
treatment and as research (Steel, Marchand, and Oveido-Joekes 2017). Instead, we argue that 
voluntariness should be understood in the context of the risk environment and frame our discussion 
within the context of the North American fentanyl crisis. Through structuring the ethical analysis of 
the permissibility of using siOAT around the contextual features of the risk environment, we propose 
and briefly outline the benefits of adopting a “situated ethics” within which we seek to balance the 
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relevant ethical considerations surrounding the provision of siOAT in the current context in which it 
is being offered. It is hoped that such a perspective provides a more holistic basis upon which to 
assess the ethics of reducing drugrelated harms. 
DECISIONAL CAPACITY, COMPETENCY, AND VOLUNTARINESS 
If PWUD are not competent to consent, then siOAT would be ethically problematic. Empirical 
evidence, however, suggests that PWUD are not incompetent to consent merely by virtue of their 
drug use. For example, Hart and colleagues demonstrated that when crack users were offered either 
crack cocaine or US$5 (or a merchandise voucher of equivalent value) they often chose the money 
over crack cocaine (Hart et al. 2000). While individual decisions, preferences, and values can change 
with drug use, we cannot presume that drug dependency alone renders PWUD unable to make 
rational trade-offs between drugs and other values or preferences. Further, the fact that some 
PWUD chose not to participate in siOAT treatment or research—as well as the fact that a significant 
number of participants drop-out of research studies of siOAT—suggests that PWUD are able to 
demonstrate the capacity to make decisions not to obtain safe drugs at no cost when offered or 
when otherwise available. While PWUD can have variable decisional capacity—as can people who do 
not use drugs—the mere fact that siOAT provides PWUD access to drugs should not be thought to 
eliminate the possibility of making situated rational decisions—insofar as we recognize that what is 
rational is largely determined by context. Since PWUD are not always, or even usually, incapable of 
demonstrating situated decisional capacity, we should not fail to provide access to siOAT on the 
basis of ethical concerns over how drug addiction may affect competence or decisional capacity. 
Despite minimizing ethical concerns about the decisional capacity of PWUD, there is still a need to 
consider whether the provision of siOAT raises any concerns about voluntariness. Charland and 
others have raised concerns about whether, in offering drug-based interventions, voluntariness 
might be compromised; it provides an option too difficult to resist (Charland 2002). In regard to 
participating in siOAT interventions, we believe that PWUD can also act voluntarily, as they have 
access to options to do otherwise and frequently demonstrate their ability to exercise those options. 
Their ability and choice to forgo the benefits of obtaining drugs in different circumstances also speak 
against the view that the provision of drugs has to be viewed as an undue inducement. The offer of 
siOAT also does not subject PWUD to coercion or take the form of forced participation. When 
attempting to evaluate whether concerns about voluntariness should raise ethical problems for 
siOAT, we suggest that voluntariness should not be understood in absolute terms. Instead, it should 
be understood as a fluid notion that is informed and defined in the context of the risk environment. 
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FENTANYL AND THE RISK ENVIRONMENT 
In recent years, fentanyl has come to define the context of injection drug use in North America. 
Between July 7, 2016, and August 3, 2016, for example, fentanyl was detected in 86% of street drugs 
provided by users of the Insite safe injection site in Vancouver, Canada (Vancouver Coastal Health 
2016). In the United States, overdose deaths attributed to fentanyl have risen from a stable level of 
1600 annually in 2010–2012 to 4200 in 2014 (Warner et al. 2016) New forms of heroin, including 
fentanyl-adulterated heroin, represent a significant change in the risk environment for PWUD 
(Ciccarone 2017). Only 0.002 g of fentanyl within 0.1 g heroin is potentially fatal; such tiny amounts 
make it almost impossible to effect a controlled dose. The existence of fentanyl-adulterated heroin, 
therefore, represents a clear and immediate danger to anyone procuring street drugs. This 
environment of heightened risk requires that we balance a concern for voluntariness with the ethical 
imperative to facilitate access to potentially lifesaving interventions (in either a treatment or a 
research context). 
Making contextual features of the risk environment prominent within an ethical analysis of 
intervention acceptability is not new. In the context of an emergency, for instance, we regularly 
undertake investigative, preventive, and therapeutic interventions in individuals and groups—
prioritizing the risk of harm to self and others over determinations of their voluntariness to consent 
(Viens and Selgelid 2012; Viens 2013). 
Therefore, in a context in which fentanyl-laced heroin poses an immediate and potentially deadly 
threat, we should forgo making voluntariness such a prominent concern in the interests of providing 
a potentially lifesaving intervention. The rationale for taking this approach is strengthened by the 
fact that the individual can do little to change or otherwise influence the risk environment and, as 
such, cannot reasonably be expected to bear personally the responsibility for avoiding fentanyl-laced 
drugs, even if the individual believes that doing so is in his or her own self-interest. 
A focus on the risk environment seeks to bring to light, and put more emphasis on, the morally 
relevant social and physical features that contribute to the probability and magnitude of drug-
related harm. It does not seek to reject or diminish potential nonmaterial harms that could result 
from providing access to siOAT to PWUD (such as those nonmaterial harms we associate with 
subjecting persons to investigative or therapeutic interventions without adequate consent). Instead, 
it puts both material and nonmaterial harms on the same scale as morally relevant considerations 
that need to be balanced—and, in some contexts, traded off against each other. When we look to 
the specific context of providing siOAT in the midst of the widespread presence of fentanyl in the 
drug supply, taking the risk environment seriously should mean that our ethical analysis will need to 
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reflect this. Finally, it is appropriate to emphasie that framing the risk environment as a central 
ethical consideration gives us the opportunity to develop a complimentary concept of the enabling 
environment, one that speaks to the ethics of enabling affected individuals the right to choose. & 
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